NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy

NCT ID: NCT04675450

Last Updated: 2023-06-08

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE2
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-06-30
• Study Completion Date: 2025-01-30

Brief Summary

Phase 2, randomized, double-blind, Placebo-Controlled, Multiple Dose Study for the treatment of Patients with Metastatic Breast Cancer.

Detailed Description

This is a multiple center, randomized, double-blind, Phase 2 study of NBP administered to women with metastatic breast cancer who receive nab-paclitaxel as therapy. Nab-paclitaxel will be administered at a dose >260 mg/m2 every 3 weeks for 4 planned cycles. Subjects will begin receiving NBP orally at a dose of 400 mg administered every 12-hours (BID) or matching placebo 5 days (10 doses) prior to starting nab-paclitaxel therapy and continue to self-administer it BID until Visit 6/Day 100/Week 15. The primary objective is to evaluate the efficacy of NBP relative to placebo at preventing or reducing symptoms associated with nab-paclitaxel induced toxic neuropathy (CIPN). The secondary objectives include an evaluation the efficacy of NBP relative to placebo at preventing or attenuating taxane induced acute pain syndrome (TAPS), the evaluation of the safety and tolerability of NBP relative to placebo and to determine if NBP administration impacts the pharmacokinetics of nab-paclitaxel or if nab-paclitaxel affects the pharmacokinetics of NBP.

Conditions

Breast Cancer; Peripheral Neuropathy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: QUADRUPLE

Study Groups

Placebo

Interventions: Placebo (NBP placebo softgel capsules, 0 mg NBP, BID)

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing

NBP

Interventions: 800 mg NBP softgel capsules daily (400 mg BID)

Group Type: ACTIVE_COMPARATOR

NBP Softgel Capsules

Intervention Type: DRUG

Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing.

Interventions

Placebo

Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing

Intervention Type: DRUG

NBP Softgel Capsules

Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing.

Intervention Type: DRUG

Other Intervention Names

NBP Placebo Softgel Capsules; NBP

Eligibility Criteria

Inclusion Criteria

Subjects are eligible to participate in the study only if all the following criteria apply:

1. Women aged ≥18 and ≤75 years.

2. Pathologically confirmed metastatic breast cancer.

3. Are candidates for initial therapy with nab-paclitaxel, at a dose of >260 mg/m2 every 3 weeks for 4 planned cycles.

4. Concomitant antitumor drugs used to treat the underlying malignancy, including immunotherapies, other than nab-paclitaxel will be allowed.

5. Eastern Cooperative Oncology Group (ECOG) performance status scores of 0 - 2.

6. Life expectancy ≥6 months.

7. Women of childbearing potential (WOCBP) must have a negative serum human chorionic gonadotropin (HCG) pregnancy test at Screening and be practicing a medically acceptable method of contraception with an annual failure rate of less than 1% until the completion of the trial or 30 days after discontinuation of study treatment. Women are considered not childbearing if they are >1 year postmenopausal or surgically sterile (ie, hysterectomy, bilateral oophorectomy, or bilateral salpingectomy tubal ligation).

8. Able to complete study questionnaires by themselves or with assistance.

9. Capable of understanding the purpose and risks of the study and able to provide informed consent by signing the informed consent form.

10. Able to swallow softgel capsules as determined by the investigator.

Exclusion Criteria

Subjects are excluded from the study if any of the following criteria apply:

1. Non-metastatic breast cancer.

2. Subjects who are pregnant, lactating/breast-feeding, or plan to become pregnant within the next 3 months.

3. History of poorly controlled diabetes mellitus (hemoglobin A1C >8.0 at the time of the Screening visit).

4. History of fibromyalgia.

5. History of any signs or symptoms suggestive of neuropathy within 30 days of Screening as determined by the investigator based on the neurological examination.

6. History of taking any neurotoxic drugs within 6 months of Screening.

7. Current use of drugs that are used to treat neuropathic pain (eg, gabapentin, pregabalin, and duloxetine) within 30 days of Screening.

8. Current diagnosis of malignancy other than breast cancer.

9. Absolute neutrophil count <1.5 x 109 cells/L.

10. Platelet count <100,000 x 109/L.

11. Hemoglobin level <9 g/dL at Screening without transfusion (transfusion independent).

12. Corrected QTcF >470 msec (single tracing) at Screening and prior to randomization.

13. Chronic renal or hepatic disease.

14. Clinically significant renal dysfunction including serum creatinine level >1.5 mg/dL or calculated creatinine clearance ≥50 mL/minute at Screening.

15. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level >2.0 x upper limits of normal (ULN), or a bilirubin >1.5 x ULN unless in the setting of known Gilbert's disease at Screening.

16. History of HIV, hepatitis B, hepatitis C, or tuberculosis.

17. Major surgical procedures ≤30 days prior to starting study drug, or minor surgical procedures ≤7 days prior to starting study drug.

18. History of alcohol or drug dependence or is known to have abused alcohol within 30 days prior to screening.

19. Unwilling to abstain from alcohol and recreational drugs (with exception for medical marijuana) throughout the duration of participation in the study.

20. Positive urine drug screen at Screening (with exception for medical marijuana which is allowed).

21. Known hypersensitivity to celery or soybeans.

22. Known serious hypersensitivity to paclitaxel

23. Received treatment with any other investigational drug within 30 days before screening, was previously treated with NBP, is currently taking celery seed extract, or is currently participating in another clinical study

24. Any other reasons that in the opinion of the investigator make the subject unsuitable for enrollment.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

CSPC-NBP Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: collaborator

Conjupro Biotherapeutics, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Qingxi Wang, PhD

Role: STUDY_DIRECTOR

Conjupro Biotherapeutics, Inc.

Other Identifiers

CPO-NBP-2002

Identifier Type: -

Identifier Source: org_study_id